Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients

Summary

This research study is evaluating an immune modulatory agent as a possible treatment for patients with Recurrent Respiratory Papillomatosis (RRP) with significant disease involving the larynx, trachea, and/or lungs. The investigators will be using Pembrolizumab as the treating agent.

Timeline

Start

2016-04

Primary completion

2022-02

Completion

2025-12

Drugs

Indications